Intratumoral Bacterial Burden Drives Immunotherapy Resistance in Head and Neck Cancer

oncodaily - Immune checkpoint blockade (ICB) benefits only a subset of patients with head and neck squamous cell carcinoma (HNSCC), and commonly used biomarkers (PD-L1, TMB) remain imperfect in this setting. This […]

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment

Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN

2 months / esmo

NIVOPOST-OP Trial: Postoperative Nivolumab Plus Cisplatin-Based Chemoradiotherapy in High-Risk Locally Advanced Head and Neck Squamous Cell Carcinoma

2 months / oncodaily

Harnessing the microbiome for cancer therapy

2 months / nature

David Sher: 2 Nature Cancer Papers on Tumor Bacterial Burden and Immunotherapy Response

2 months / oncodaily

Global Incidence of Lip, Oral Cavity, and Pharyngeal Cancers – American Cancer Society Journals

2 months / oncodaily

Intratumoral Bacterial Burden Drives Immunotherapy Resistance in Head and Neck Cancer

2 months / oncodaily

Tumor bacteria linked to immunotherapy resistance in head and neck cancer

2 months / medicalxpress

Back to Top / Saturday, January 3, 2026, 11:20 am / permalink 17458 / 7 stories in 2 months




Related Stories

NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.